CTOs on the Move

CureVac

www.curevac.com

 
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing this versatile biological molecule for medical purposes. The principle of CureVac`s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac`s second-generation mRNA technology. This collaboration was later extended to the ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.curevac.com
  • 250 Summer Street 3rd Floor
    Boston, MA USA 02210
  • Phone: 617.377.4040

Executives

Name Title Contact Details
Patrick Baumhof
Senior Vice President of Technology Profile
Mariola Fotin-Mleczek
Chief Technology Officer Profile
Mariola Fotin-Mleczek
Chief Technology Officer Profile

Similar Companies

Advantage Care Services

Advantage Care Services is a Asheville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HiFiBiO - High Fidelity Biology

HiFiBiO SAS commercializes proprietary single cell technologies for applications in drug and biomarker discovery and development.

Bioriginal Food and Science

Bioriginal Food and Science Corp. is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Just. Biotherapeutics

Just. is an integrated design company focused on the technology of biotherapeutics, from molecule to manufacturing plant. We believe that technological innovation will accelerate biotherapeutic development and dramatically reduce the cost of these vital medicines.

Deep Genomics

Our founding belief is that the future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. Today, the molecular world of the cell can be experimentally interrogated like never before. The resulting datasets provide an unprecedented opportunity to build artificial intelligence systems that are biologically accurate and that support the detection of disease and the development of molecular interventions. Deep Genomics is building a biologically accurate data- and AI-driven platform that supports geneticists, molecular biologists and chemists in the development of therapies. Over the next two years, Deep Genomics will use its platform to unlock new classes of antisense oligonucleotide therapies that were previously inaccessible or out of reach, and advance them for clinical evaluation. In project Saturn, the platform will be used to search across a vast space of over 69 billion molecules with the goal of generating a library of 1000 compounds that can be used to manipulate cell biology and design therapies.